title: Treatment of systemic-onset juvenile arthritis with canakinumab.
abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis.
authors: Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany.
authors: Joachim
authors: J
authors: Peitz
authors: Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany.
authors: Gerd
authors: G
authors: Horneff
keywords: anakinra; canakinumab; interleukin-1; interleukin-6; systemic-onset juvenile idiopathic arthritis